Efficacy and safety of infliximab therapy in refractory upper respiratory tract sarcoidosis : experience from the STAT registry
Copyright: © 2017..
Background: Upper respiratory tract (URT) involvement in sarcoidosis may be refractory to corticosteroids and immunosuppressants. Whether TNF-antagonists are efficient and safe in such phenotype is unknown. Methods: STAT is a French national drug registry including patients presenting sarcoidosis treated with TNF alpha antagonists. All cases of biopsy-proven sinonasal and laryngeal sarcoidosis were extracted and retrospectively analyzed from July 2014 to July 2015. Results: Twelve patients presenting biopsy-proven sarcoidosis with URT involvement were included in the STAT registry. Infliximab appeared effective in decreasing URT symptoms, as assessed by a significant decrease of the e-POST (extra-pulmonary Physician Organ Severity Tool) (1.5 [0-2] vs 5 [1.5-5], p=0.03) and a corticosteroids-sparing effect (7.5mg per day [5-10] vs 17.5 mg per day [7.5-20], p=0.04) at the end of follow-up. Conclusions: TNF-antagonists may be an efficient treatment of refractory URT manifestations and should be discussed when prolonged or high dosages of corticosteroids despite immunosuppressive therapy are required. (Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 343-351).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG - 34(2017), 4 vom: 21., Seite 343-351 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barba, Thomas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 13.11.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.36141/svdld.v34i4.5817 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310572983 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310572983 | ||
| 003 | DE-627 | ||
| 005 | 20231225140405.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.36141/svdld.v34i4.5817 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM310572983 | ||
| 035 | |a (NLM)32476867 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barba, Thomas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of infliximab therapy in refractory upper respiratory tract sarcoidosis |b experience from the STAT registry |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2017. | ||
| 520 | |a Background: Upper respiratory tract (URT) involvement in sarcoidosis may be refractory to corticosteroids and immunosuppressants. Whether TNF-antagonists are efficient and safe in such phenotype is unknown. Methods: STAT is a French national drug registry including patients presenting sarcoidosis treated with TNF alpha antagonists. All cases of biopsy-proven sinonasal and laryngeal sarcoidosis were extracted and retrospectively analyzed from July 2014 to July 2015. Results: Twelve patients presenting biopsy-proven sarcoidosis with URT involvement were included in the STAT registry. Infliximab appeared effective in decreasing URT symptoms, as assessed by a significant decrease of the e-POST (extra-pulmonary Physician Organ Severity Tool) (1.5 [0-2] vs 5 [1.5-5], p=0.03) and a corticosteroids-sparing effect (7.5mg per day [5-10] vs 17.5 mg per day [7.5-20], p=0.04) at the end of follow-up. Conclusions: TNF-antagonists may be an efficient treatment of refractory URT manifestations and should be discussed when prolonged or high dosages of corticosteroids despite immunosuppressive therapy are required. (Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 343-351) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a TNF antagonists | |
| 650 | 4 | |a refractory sarcoidosis | |
| 650 | 4 | |a upper respiratory tract | |
| 700 | 1 | |a Marquet, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Bouvry, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen-Aubart, Fleur |e verfasserin |4 aut | |
| 700 | 1 | |a Ruivard, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Debarbieux, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Khouatra, Chahéra |e verfasserin |4 aut | |
| 700 | 1 | |a Vighetto, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a de Parisot, Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Valeyre, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Sève, Pascal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG |d 1996 |g 34(2017), 4 vom: 21., Seite 343-351 |w (DE-627)NLM088329399 |x 1124-0490 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2017 |g number:4 |g day:21 |g pages:343-351 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.36141/svdld.v34i4.5817 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2017 |e 4 |b 21 |h 343-351 | ||